ライフサイエンスコーパス: CAR

1 ric TCRs or synthetic chimeric Ag receptors (CARs).

2 t for both direct and indirect activation of CAR.

3 A549 cells, suggesting a potential role for CAR.

4 nalling tail and named the final product TCR-CAR.

5 reet scenes gathered with Google Street View cars.

6 sion methane analyzers in Google Street View cars.

7 ma team members as competent, efficient, and caring.

8 uman coxsackievirus and adenovirus receptor [CAR]).

9 Patients received a single dose of CAR-19 T cells 2 days after a low-dose chemotherapy cond

10 esults supporting treatment of lymphoma with CAR-19 T cells have been published.

11 Conclusion CAR-19 T cells preceded by low-dose chemotherapy induced

12 CAR-19 T cells will likely become an important treatment

13 ric antigen receptors (CARs) targeting CD19 (CAR-19) have potent activity against acute lymphoblastic

14 ds with finished floors, a television, and a car; 3) were born to highly educated mothers; 4) were si

15 FICANCE STATEMENT Whether searching for your car, a particular item of clothing, or just obeying traf

16 admitted to the emergency department after a car accident.

17 nderlying molecular mechanism that regulates CAR activation, by placing phosphorylated threonine 38 a

18 of the canonical anticommutation relations (CAR) algebra.

19 Moreover, the NLRC3 CARD alone could dampen IL-1beta secretion and ASC speck

20 Once RPo forms, CarD also disfavors its isomerization back to RP2.

21 Interestingly, at high Ag density, CARs also mediated greater maximal release of some cytok

22 Furthermore, CAR and DeltaCAR Tregs preferentially transmigrated acro

23 ansduction in a FX-independent manner in CHO-CAR and SKOV3-CAR cells (CHO or SKOV3 cells transfected

24 could drastically improve the efficiency of car and taxi transportation.

25 should always carry a C1-INH-HAE information card and medicine for emergency use.

26 enhouse-gas emission standards for passenger cars and light trucks.

27 Representative material contents in cars and light-duty trucks are estimated using comprehen

28 nd SFG imaging was faster, but hyperspectral CARS and SFG imaging has the potential to be applied to

29 Simultaneous narrowband CARS and SFG imaging was faster, but hyperspectral CARS

30 SFG imaging and (ii) simultaneous narrowband CARS and SFG imaging.

31 s-associated speck-like protein containing a CARD) and pro-caspase-1, as well as its downstream targe

32 cts, using both natural stimuli (prestigious cars) and laboratory-tagged stimuli of matched value (un

33 ties, coherent anti-Stokes Raman scattering (CARS) and sum-frequency generation (SFG), were successfu

34 P3, disrupts ASC speck formation through its CARD, and impairs the ASC and pro-caspase-1 interaction.

35 For example, people and cars appear to move across the field of view at the same

36 RbpA and CarD are essential transcription regulators in mycobacte

37 Many CARs are designed with elements that augment T cell pers

38 CARs are synthetic receptors that reprogram immune cells

39 Chimeric antigen receptors (CAR) are clinically translatable synthetic fusion protei

40 Chimeric antigen receptors (CARs) are fusion proteins incorporating antigen-recognit

41 vides a basic framework to use a multi-chain CAR as a platform to create the next generation of smart

42 ehensively explore the potential role of the CAR as a prognostic indicator in solid cancers.

43 s-associated speck-like protein containing a CARD (ASC) protein in response to NALP3 activators.

44 OA formation from modern diesel and gasoline cars at different temperatures (22, -7 degrees C) during

45 Transduction of HAdV-5 KO1 and HAdV-5/F35 (CAR binding deficient) in the presence of Rag 2(-/-) ser

46 After modification with the SLAMF7-CAR, both CD8(+) and CD4(+) T cells rapidly acquired and

47 thylpentyl)-tetrahydro-13-methyl-2H-pyran-17-car boxylate (2) and (13-(methoxycarbonyl)-11-((E)-18-et

48 imensional gel electrophoresis revealed that CAR can form a homodimer in a configuration in which the

49 Carboxylic acid reductases (CARs) catalyze the reduction of a broad range of carboxy

50 troviral vector to express the CD30-specific CAR (CD30.CAR-Ts) encoding the CD28 costimulatory endodo

51 achieve a remission had a median peak blood CAR(+) cell level of 15/muL ( P = .027).

52 achieved a remission had a median peak blood CAR(+) cell level of 98/muL and those who did not achiev

53 a FX-independent manner in CHO-CAR and SKOV3-CAR cells (CHO or SKOV3 cells transfected to stably expr

54 es were used and compared: (i) hyperspectral CARS combined with principal component analysis (PCA) an

55 s-associated speck-like protein containing a CARD complex), or caspase-1 protected against PDA and wa

56 We here show that, if expressed, the TCR-CAR conserved the specificity and the functionality of t

57 Nod-like receptor family card containing 4 (NLRC4)/Ipaf is involved in recognitio

58 LRC3) protein, a caspase recruitment domain (CARD)-containing member of the nucleotide oligomerizatio

59 NLR family CARD-containing 3 (NLRC3) protein, a caspase recruitment

60 ipitation revealed interaction of NLRP1 with CARD-containing caspase-2 and -9, whereas NLRP3 lacking

61 g pathways that periodically reconnect, like cars controlled by traffic lights.

62 plex (RPo) formation establish that RbpA and CarD cooperatively stimulate formation of an intermediat

63 tokines), cardiac fibrosis, apoptosis, lower CAR (Coxsackievirus and adenovirus receptor) expression

64 ologous T cells that express a CD19-directed CAR (CTL019) to treat patients with diffuse large B-cell

65 CARD curation is updated monthly based on an interplay o

66 e, EGF signaling weakened the interaction of CAR DBD T38D with CAR LBD, converting CAR to the homodim

67 Asp increased co-immunoprecipitation of the CAR DBD with CAR LBD in Huh-7 cells.

68 nant CAR DBD-T38D, but not nonphosphorylated CAR DBD, bound the CAR LBD peptide.

69 imetry assays also revealed that recombinant CAR DBD-T38D, but not nonphosphorylated CAR DBD, bound t

70 d CAR-DCN groups, the severity of AAA in the CAR-DCN group was significantly reduced.

71 lence of AAA was similar between vehicle and CAR-DCN groups, the severity of AAA in the CAR-DCN group

72 study, the role of systemically-administered CAR-DCN in AAA progression and rupture was assessed in a

73 to AAA rupture was significantly reduced in CAR-DCN-treated mice compared to controls.

74 CARs demonstrated amidation activity for various acids a

75 Investigating CARS-dependent persulfide production may thus clarify ab

76 h expression of a chimeric antigen receptor (CAR) derived from the huLuc63 antibody (elotuzumab) and

77 low-cost reader and disposable lateral flow card designed to measure the concentration of total bili

78 Chimeric antigen receptors (CARs) direct tumor cell recognition of adoptively transf

79 is-associated speck-like molecule containing CARD domain (Asc) at the protein and RNA levels.

80 optosis-associated speck-like protein with a CARD domain oligomerization, and caspase-1 processing, k

81 main, leucine-rich repeat-containing family, CARD domain-containing protein 4 (NLRC4) inflammasome up

82 , caspase activation and recruitment domain (CARD) domain containing 5], is a key transcription coact

83 runcated CARD8 protein lacking the FIIND and CARD domains.

84 sing an equimolar concentration library, the CaR-ESI-MS assay identified 100% of ligands with affinit

85 Notably, for each lectin, CaR-ESI-MS screening required <1 h to complete and consu

86 ve T cells expressing CD28-costimulated CD19 CARs experience enhanced stimulation, resulting in the p

87 ant (TRAC) locus not only results in uniform CAR expression in human peripheral blood T cells, but al

88 duct of defined CD4/CD8 composition, uniform CAR expression, and limited effector differentiation.

89 s-associated speck-like protein containing a CARD) expression, caspase 1 activity, or IL-1beta (inter

90 The analysis of the passenger car fleet development in the city of Copenhagen for the

91 ive internalization and re-expression of the CAR following single or repeated exposure to antigen, de

92 and non-accommodation states) reported they cared for a pediatric patient whose family requested con

93 S with genetically confirmed SOD1 mutations, cared for after the year 2000.

94 m January 1, 2005, to December 31, 2014, and cared for at 756 Vermont Oxford Network member NICUs in

95 ologic specimens were obtained from patients cared for at the University of Iowa and Washington Unive

96 ohort study of almost 4000 patients with HCC cared for at VA centers, geographic, provider, and syste

97 gs were corroborated in a cohort of patients cared for at Vanderbilt University, an academic referral

98 g utilization in a stable cohort of patients cared for by PCPs during a 7-year period showed that com

99 om are Medicaid insured and 6000 of whom are cared for in Cincinnati Children's Hospital primary care

100 l patients requiring critical resources were cared for in major trauma centers vs 88.7% of urban pati

101 nt ischemic attack or minor ischemic stroke, cared for in Veterans Health Administration facilities (

102 r were treated by an attending physician who cared for less than five study patients were excluded.

103 e emergency physicians within a hospital who cared for the patients, we categorized the physicians as

104 Those caring for 1-5 patients per shift and those providing fu

105 s 10.6 minutes [95% CI, 5.3-16.0] for nurses caring for 2 or more patients), if there were prior alar

106 e 'weekend effect' at a major trauma centre, caring for acute injuries.

107 These findings highlight the importance of caring for caregivers as well as patients when attemptin

108 rs from tertiary care centers experienced in caring for children with OPPN, was convened to address t

109 creasingly utilized to fill resource gaps in caring for critically ill patients.

110 any short- or long-term survival costs from caring for cubs, but extending care reduced the number o

111 They must manage the dual obligation of caring for dying patients and their families while provi

112 ations The ASCO Expert Panel emphasized that caring for HNC survivors requires a team-based approach

113 For clinicians caring for patients requiring liver transplant, the key

114 ht some of the more controversial aspects of caring for patients with anorectal malformation and offe

115 uthors' considerable lifetime experiences in caring for patients with ARVC.

116 ntextualise the recommendation for providers caring for patients with IPF.

117 Physicians caring for patients with primary immunodeficiency diseas

118 s identified in training provision included: caring for people with cognitive impairment; managing th

119 iplinary management of obesity as physicians caring for people with obesity-related diseases, in addi

120 d more likely to have little experience with caring for potential organ donors (odds ratio, 1.49; 95%

121 atient was a nurse who became infected while caring for the index patient.

122 ebate by people living with cancer and those caring for them.

123 listic, posing challenges for the clinicians caring for them.

124 in high-risk patients, especially at centers caring for vulnerable and low-income patients.

125 ent materials, all formulated under a credit card format, were incubated in an outdoor compost to eva

126 The DBD-T38D-LBD interaction also prevented CAR from forming a heterodimer with RXRalpha.

127 Cardiac Arrest Registry to Enhance Survival (CARES) from January 1, 2010, through December 31, 2014.

128 role played by antigen density in regulating CAR function.

129 an efficiently introduce leukaemia-targeting CAR genes into T-cell nuclei, thereby bringing about lon

130 her reaction with fluorobenzene afforded the CAr -H bond activation product [1-F-2-IMe -C6 H4 ](+) I(

131 nsitivity and signaling capacity of TCRs and CARs has been limited due to their differences in affini

132 ion masked CAR's dimer interface, preventing CAR homodimer formation.

133 l growth factor (EGF) was found to stimulate CAR homodimerization, thus constraining CAR in its inact

134 Analysis of multiplex CARS images can distinguish between molecular components

135 iplex coherent anti-Stokes Raman scattering (CARS) imaging via supercontinuum excitation to probe mor

136 These findings uncover facets of CAR immunobiology and underscore the potential of CRISPR

137 o determine all areas that can be reached by car in a user-specified amount of time.

138 late CAR homodimerization, thus constraining CAR in its inactive form.

139 be conducted to explore the critical role of CAR in survival of cancer patients.

140 icating hematologic malignancies (e.g., CD19 CARs in leukemias).

141 using data from state-level land registries (CAR) in Para and Mato Grosso that were precursors of SIC

142 CAR inactivates its constitutive activity by phosphoryla

143 -ribosyl polymerase expression and inhibited CAR-induced apoptosis.

144 Treatment with BAY 11-7082 or BBG 1 h after CAR injection attenuated pulmonary membrane thickening a

145 g that direct interaction between HAdV-5 and CAR is not required.

146 CARD is ontologically structured, model centric, and spa

147 d co-immunoprecipitation of the CAR DBD with CAR LBD in Huh-7 cells.

148 but not nonphosphorylated CAR DBD, bound the CAR LBD peptide.

149 eakened the interaction of CAR DBD T38D with CAR LBD, converting CAR to the homodimer form.

150 g a CD30-specific chimeric antigen receptor (CAR) may reduce the side effects and augment antitumor a

151 In both neonatal and adult hUGT1/Car(-/-) mice, PEITC was unable to induce CYP2B10.

152 using coherent anti-Stokes Raman scattering (CARS) microscopy and isotopic perfusion experiments.

153 and coherent anti-Stokes Raman spectroscopy (CARS) microspectroscopy allowed us to locally identify a

154 he application of chimeric antigen receptor (CAR)-modified T cells in cancer immunotherapy.

155 the fate and function of individually sorted CAR-modified T cell subsets after activation with CD3 an

156 ll populations to the CD3 and CD28-activated CAR-modified T cells that we use for therapy, we followe

157 ful tool to elucidate the characteristics of CAR-modified T cells, regardless of the protocol used fo

158 le filter (DPF) and catalyst-equipped diesel cars, more so at -7 degrees C, contrasting with nitrogen

159 ng caspase-2 and -9, whereas NLRP3 lacking a CARD motif did not interact with the caspases.

160 Target antigens for CARs must be expressed on malignant cells, but expressio

161 ever, TSB levels were still reduced in hUGT1/Car(-/-) neonatal mice because of ROS induction of intes

162 The nuclear receptor CAR (NR1I3) regulates hepatic drug and energy metabolism

163 e-in-one" policy, which required all private cars on two major roads to carry at least three passenge

164 ein constitutive active/androstane receptor (CAR or NR1I3) regulates several liver functions such as

165 Under optimal experimental conditions (DVB/CAR/PDMS fibre coating, 40 degrees C, 30min extraction t

166 icroextraction, such as fiber coating (85mum CAR/PDMS), extraction time (2min for white and 3min for

167 s at the core of human personality: SEEKING, CARING, PLAYFULNESS, FEAR, ANGER, SADNESS.

168 The constitutive androstane receptor (CAR) plays an important role in xenobiotic metabolism, e

169 oblastic leukemia was conducted using a CD19 CAR product of defined CD4/CD8 composition, uniform CAR

170 By coexpression of two differently tagged CAR proteins in Huh-7 cells, mouse primary hepatocytes,

171 tiation complex (TIC) with RbpA as well as a CarD/RbpA/TIC model.

172 Although very potent, CAR recognition is limited to membrane antigens which re

173 In addition, we demonstrate that TCR-CAR redirection was not restricted to T cells.

174 of the DNA-binding domain (DBD) at Thr-38 in CAR regulates this conversion.

175 Antagonism of the CAR represents a key strategy for studying its function

176 This DBD-LBD interaction masked CAR's dimer interface, preventing CAR homodimer formatio

177 oxygen sensitive subdomain of HIF1alpha to a CAR scaffold, we generated CAR T-cells that are responsi

178 helmet use for motorcyclists and bicyclists, car seat and booster seat use for child motor vehicle pa

179 t high risk for polio transmission with a RI card seen, from 23% to 56%, and an overall increase in f

180 athematical modeling demonstrated that lower CAR sensitivity could be attributed to less efficient si

181 CARD-SGS is a useful tool to characterize fractional pro

182 Spiking experiments show that the CARD-SGS method can detect a single cell expressing HIV

183 Applying CARD-SGS to blood mononuclear cells in six samples from

184 Generation of the CARS signal is optimized for water imaging with broadban

185 eting the CAR to the TRAC locus averts tonic CAR signalling and establishes effective internalization

186 We have fused a soluble TCR construct to a CAR-signalling tail and named the final product TCR-CAR.

187 Importantly, the CARS signals from cellular sheddings from MCAs with LPA

188 induced fluorescence detection and a credit card sized minicomputer to prove the concept of real tim

189 d microfluidic chip embedded within a credit-card-sized cartridge.

190 bserved at high Ag density for both TCRs and CARs suggested a role for negative regulators in both sy

191 In vivo, we show enhanced expansion and CAR T cell antitumor efficacy, culminating in improvemen

192 We engineered an armored CAR T cell capable of constitutive secretion of IL-12, a

193 Pdcd1 (PD-1) disruption augmented CAR T cell mediated killing of tumor cells in vitro and

194 ned disruption of inhibitory checkpoints and CAR T cell therapy remains incompletely explored.

195 However, CAR T cell treatments are less effective in solid tumors

196 In this study, we developed a CAR T cell-based immunotherapeutic strategy to target TE

197 ) expression on tumor cells can render human CAR T cells (anti-CD19 4-1BBzeta) hypo-functional, resul

198 ted patients infused with donor-derived CD19 CAR T cells after allo-HSCT.

199 ity compared with treatment with either HER2.CAR T cells alone or HER2.CAR T cells plus Onc.Ad.

200 of a target antigen overcomes fratricide of CAR T cells and establishes the feasibility of using CD7

201 ients with AML treated with CD123-redirected CAR T cells and mandates novel approaches for toxicity m

202 recognition of normal lymphocytes by SLAMF7-CAR T cells and show that they induce selective fratrici

203 These CAR T cells are engineered to express synthetic receptor

204 Autologous CAR T cells are generated from the patient's peripheral

205 e of the inhibitory microenvironment and how CAR T cells can be further engineered to maintain effica

206 ancreatic cancer and melanoma, we found that CAR T cells can migrate from biopolymer scaffolds and er

207 Consequently, SLAMF7-CAR T cells conferred rapid cytolysis of previously untr

208 emic off-tumor toxicity, micromolar affinity CAR T cells demonstrated superior anti-tumor efficacy an

209 implantable biopolymer devices that deliver CAR T cells directly to the surfaces of solid tumors, th

210 However, combining CAd-VECPDL1 with HER2.CAR T cells enhanced antitumor activity compared with tr

211 and establishes the feasibility of using CD7 CAR T cells for the targeted therapy of T-cell malignanc

212 However, treatment of solid tumors using CAR T cells has been largely unsuccessful to date, partl

213 To date, CAR T cells have demonstrated tremendous success in erad

214 astly outperforming conventionally generated CAR T cells in a mouse model of acute lymphoblastic leuk

215 addition, a single administration of SLAMF7-CAR T cells led to resolution of medullary and extramedu

216 and delineate the mechanisms via which these CAR T cells overcome a hostile tumor microenvironment.

217 received a target dose of 2x10(6) anti-CD19 CAR T cells per kilogram of body weight after receiving

218 t with either HER2.CAR T cells alone or HER2.CAR T cells plus Onc.Ad.

219 However, the use of allogeneic CAR T cells poses a concern in that it may increase risk

220 ody (elotuzumab) and demonstrate that SLAMF7-CAR T cells prepared from patients and healthy donors co

221 however, the fratricide conferred by SLAMF7-CAR T cells spares the SLAMF7(-/low) fraction in each ce

222 Transduced ANS8 CAR T cells specific for the A2 domain proliferated in r

223 Notably, the TEM8 CAR T cells targeted breast cancer stem-like cells, offs

224 arget antigens and restricted trafficking of CAR T cells to and impaired long-term persistence at the

225 Although CD7 CAR T cells were also toxic against unedited (CD7(+)) T

226 liferation marker Ki67 in tumor-infiltrating CAR T cells when combined with alpha-4-1BB.

227 this fratricide and enabled expansion of CD7 CAR T cells without compromising their cytotoxic functio

228 Chimeric antigen receptor-modified T cells (CAR T cells) produce proinflammatory cytokines that incr

229 contraction kinetics of micromolar affinity CAR T cells.

230 duction to generate PD-1 deficient anti-CD19 CAR T cells.

231 y of cases of grade >/=4 CRS occurred during CAR T-cell dose finding.

232 here that alpha-4-1BB significantly enhanced CAR T-cell efficacy directed against the Her2 antigen in

233 (mini-body; HDPDL1) as a strategy to enhance CAR T-cell killing.

234 Higher CAR T-cell levels in blood were associated with response

235 ted that durable leukemia remission required CAR T-cell persistence for 4 weeks prior to ablation.

236 1BB has a multifunctional role for enhancing CAR T-cell responses and that this combination therapy h

237 To test this hypothesis, we compared 3 CAR T-cell termination strategies: (1) transiently activ

238 e, as well as the unaddressed integration of CAR T-cell therapy into conventional anticancer treatmen

239 esized that a combination of alpha-4-1BB and CAR T-cell therapy would result in improved antitumor re

240 cilitate safer application of effective CD19 CAR T-cell therapy.

241 Here we present a strategy to generate CAR T-cells that are only effective locally (tumor tissu

242 of HIF1alpha to a CAR scaffold, we generated CAR T-cells that are responsive to a hypoxic environment

243 ong with the development of oxygen-sensitive CAR T-cells, this work also provides a basic framework t

244 t generation of smarter self-decision making CAR T-cells.

245 Chimeric antigen receptor (CAR) T cell therapy has shown limited efficacy for the m

246 he application of chimeric antigen receptor (CAR) T cell therapy in cancers.

247 unotherapies with chimeric antigen receptor (CAR) T cells and checkpoint inhibitors (including antibo

248 In this study, chimeric antigen receptor (CAR) T cells expressing EGFRvIII targeting transgene wer

249 specific chimeric antigen receptor-modified (CAR) T cells has produced impressive antitumor responses

250 Chimeric antigen receptor (CAR) T cells have been highly successful in treating hem

251 Chimeric antigen receptor (CAR) T cells have proven that engineered immune cells ca

252 CD123-redirected chimeric antigen receptor (CAR) T cells in preclinical human acute myeloid leukemia

253 eloped anti-TRBC1 chimeric antigen receptor (CAR) T cells, which recognized and killed normal and mal

254 Chimeric antigen receptor (CAR) T-cell therapy is an emerging immunotherapy against

255 survival (median 6.6 months follow-up) after CAR-T cell immunotherapy.

256 Conclusion CD19 CAR-T cells are highly effective in high-risk patients w

257 17 patients (88%) with marrow disease before CAR-T cells had no disease by flow cytometry after CAR-T

258 ys 0 to 90 in 133 patients treated with CD19 CAR-T cells in a phase 1/2 study.

259 cells had no disease by flow cytometry after CAR-T cells.

260 as discontinued at least 4 weeks before CD30.CAR-T infusion.

261 CAR-T therapies for MM are at an early stage of developm

262 rgeted chimeric antigen receptor-modified T (CAR-T)-cell immunotherapy is a novel treatment for refra

263 titumor regimens, and receipt of the highest CAR-T-cell dose (2 x 10(7) cells per kg) had a higher in

264 ome (CRS) severity was the only factor after CAR-T-cell infusion associated with infection in a multi

265 0 of 133 patients (23%) within 28 days after CAR-T-cell infusion with an infection density of 1.19 in

266 infection occurred a median of 6 days after CAR-T-cell infusion.

267 We developed a TaqMan array card (TAC) that detects multiple pathogens simultaneousl

268 efinition of 2+) were tested by TaqMan array card (TAC), a multipathogen real-time PCR detection plat

269 cells, and a single-chain variable fragment CAR targeting BCMA alone resulted in outgrowth of a BCMA

270 CARs targeting CD19 have demonstrated remarkable potency

271 ified to express chimeric antigen receptors (CARs) targeting CD19 (CAR-19) have potent activity again

272 kappa light chain are under investigation as CAR targets.

273 Our results demonstrated that the use of CAR technology is a clinically applicable refinement of

274 cells modified by chimeric antigen receptor (CAR) that target CD19 in B-cell cancers, although data r

275 veral target pairings hold great promise for CAR therapy of AML.

276 terials that bear large cyclic loads such as car tires or bearing sealants.

277 n of phosphorylated DBD with the LBD enables CAR to adapt a transient monomer configuration that can

278 ion of CAR DBD T38D with CAR LBD, converting CAR to the homodimer form.

279 Here we show that directing a CD19-specific CAR to the T-cell receptor alpha constant (TRAC) locus n

280 We further demonstrate that targeting the CAR to the TRAC locus averts tonic CAR signalling and es

281 Importantly, ANS8 CAR-transduced Tregs also were able to suppress the reca

282 n proliferated in response to FVIII and ANS8 CAR Tregs were able to suppress the proliferation of FVI

283 CAR Tregs were specifically activated and significantly

284 CD30.CAR-Ts are safe and can lead to clinical responses in pa

285 ed CD19(+) myeloma stem cells with anti-CD19 CAR-Ts is a novel approach to MM therapy.

286 CAR-Ts targeting B-cell maturation antigen have demonstr

287 No toxicities attributable to CD30.CAR-Ts were observed.

288 ector to express the CD30-specific CAR (CD30.CAR-Ts) encoding the CD28 costimulatory endodomain.

289 required for effective treatment of MM with CAR-Ts.

290 dose levels, from 0.2 x 108 to 2 x 108 CD30.CAR-Ts/m2, were infused without a conditioning regimen.

291 TCRs recognize peptide-HLA complexes whereas CARs typically use an Ab-derived single-chain fragments

292 CAR undergoes a conversion from inactive homodimers to a

293 rdised collection of exacerbations and diary card variables, were used to construct and test CompEx.

294 d ileum ASBT and decreased liver IL-10, FXR, CAR, VDR, BSEP, MRP2, MRP3, MRP4 was also observed in AN

295 Further evaluation of HER2-CAR VSTs in a phase 2b study is warranted as a single ag

296 Mechanistic understanding of CARs was used to expand reaction scope, generating bioca

297 Additionally, blockade of CAR with soluble HAdV-5 fiber knob inhibited mouse serum

298 Our results indicate rapid adoption of CAR, with registered properties covering a total of 57 M

299 I: 1.58-2.56, p < 0.001) indicated that high CAR yielded worse survival in different cancers.

300 sion protein complexes (e.g., occludin-ZO-1, CAR-ZO-1, and N-cadherin-ss-catenin), through a down-reg